HPLC, UHPLC
Fast and Easy Achiral & Chiral Analysis of Cannabinoids
May 20 2019
It has been repeatedly suggested that the effect of Δ9-Tetrahydrocannabinol (THC) or other single cannabinoids are not equal to that of whole cannabis preparations: some of the bio-activity observed for these preparations could be due to acidic cannabinoids. That is why a method which separates both neutral compounds such as THC as well as acidic cannabinoids such as THCA in plant material must be available.
In Europe there is a growing interest in medicinal cannabis, which is used to treat a series of pathologies. Nonetheless, cannabis is a strictly controlled drug under specific regulations or is illegal even for therapeutic purposes in many European countries. Certified medicinal cannabis is currently used for the treatment of a number of pathologies, including multiple sclerosis, epilepsy, neuropathic pain, arthritis, depression, anxiety disorders, sleep disorders, psychosis, glaucoma and Tourette’s syndrome. It is also used for the relief of symptoms such as nausea and vomiting as a result of chemotherapy, and appetite stimulation in patients suffering from HIV and AIDS.
The cannabinoids form a group of related compounds of which about 70 are known. Among the major cannabinoids in Cannabis sativa L. THC is generally accepted to be the compound that possesses the psychoactive properties.
The analysis of the original composition of plant material is necessary for such purposes as phenotyp determination and quality control of medical cannabis used for therapeutic treatment. HPLC permits the determination of the original composition of plant cannabinoids by direct analysis.
This application note describes two fast methods for separating different cannabinoids using YMC-Triart C18 UHPLC column and YMC’s Core-Shell Meteoric Core C18 column. A third rapid method shows a method for the chiral separation of THC isomers using the polysaccharide CHIRAL ART Amylose-C column.
Events
Jan 20 2025 Amsterdam, Netherlands
Feb 03 2025 Dubai, UAE
Feb 05 2025 Guangzhou, China
Mar 01 2025 Boston, MA, USA
Mar 04 2025 Berlin, Germany